Pharmacokinetic and pharmacodynamic considerations of antimicrobial therapy in sepsis

Anestezjologia Intensywna Terapia

Volumn 39, Issue 3, 2007, Pages 136-143

  Smuszkiewicz, Piotr ^a,c   Szałek, Edyta ^a   Tomczak, Hanna ^b   Trojanowska, Iwona ^a   Błaszyk, Maciej ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b Central Microbiological Laboratory   (Poland)

^c Klinika Anestezjologii Intensywnej Terapii i Leczenia Bólu   (Poland)

Author keywords

Antibiotic, betalactam; Antibiotics, aminoglycosides; Antibiotics, clindamycin; Antibiotics, macrolides; Sepsis, antimicrobial therapy

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZITHROMYCIN; AZTREONAM; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CATECHOLAMINE; CEFEPIME; CEFOTAXIME; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; DIURETIC AGENT; ERYTHROMYCIN; IMIPENEM; LINEZOLID; MACROLIDE; MEROPENEM; METRONIDAZOLE; MONOBACTAM DERIVATIVE; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TEICOPLANIN; TETRACYCLINE; UNINDEXED DRUG;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; AREA UNDER THE CURVE; CONTINUOUS INFUSION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; HUMAN; INTENSIVE CARE UNIT; LIVER DISEASE; LOADING DRUG DOSE; LOW DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; PATHOPHYSIOLOGY; PHARMACODYNAMICS; PREDICTION; RECOMMENDED DRUG DOSE; REVIEW; RISK ASSESSMENT; SEPSIS; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT;

EID: 35648991446     PISSN: 02091712     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Pea F, Viale P, Furlanut M: Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet 2005; 44: 1009-1034.
2. Hotchkiss RS, Karl IE: The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348: 138-150.
3. Barger A, Fuhst C, Wiedemann B: Pharmacological indices in antibiotic therapy. J Antimicrob Chemother 2003; 52: 893-898.
4. Mehrotra R, De Gaudio R, Palazzo M: Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness. Intensive Care Med 2004; 30: 2145-2158.
5. Highet VS, Forrest A, Ballow C, Schentag JJ: Anibiotic dosing issues in lower respiratory tract infection: population-derived area under inhibitory curve is predictive of efficacy. J Antimicrob Chemother 1999; 43 (Suppl. A): 55-63.
6. Pinder M, Bellomo R, Lipman J: Pharmacological principles of antibiotic prescription in the critically ill. Anaesth Intensive Care 2002; 30: 134-144.
7. Wada DR, Drover DR, Lemmens HJ: Determination of the distribution volume that can be used to calculate the intravenous loading dose. Clin Pharmacokinet 1998; 35: 1-7.
8. De Paepe P, Belpaire FM, Buylaert WA: Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock. Clin Pharmacokinet 2002; 41: 1135-1151.
9. Botha FJ, van der Bijl P, Seifart HI, Parkin DP: Fluctuation of the volume of distribution of amikacin and its effect on once-daily dosage and clearance in a seriously ill patient. Intensive Care Med 1996; 22: 443-446.
10. Buijk SL, Gyssens IC, Mouton JW, van Vliet A, Verbrugh HA, Bruining HA: Pharmacokinetics of ceftazidime in serum and peritoneal exudate during continuous versus intermittent administration to patients with severe intra-abdominal infections. J Antimicrob Chemother 2002; 49: 121-128.
11. Pea F, Porreca L, Baraldo M, Furlanut M: High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures. J Antimicrob Chemother 2000; 45: 329-335.
12. Craig WA: Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-10.
13. Muller M, dela Pena A, Derendorf H: Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue. Antimicrob Agents Chemother 2004; 48: 1441-1453.
14. Roberts JA, Lipman J: Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clin Pharmacokinet 2006; 45: 755-773.
15. Schentag JJ, Nix DE, Forrest A, Adelman MH: AUIC - the universal parameter within the constraint of a reasonable dosing interval. Ann Pharmacother 1996; 30: 1029-1031.
16. Nicolau DP: Optimizing outcomes with antimicrobial therapy through pharmacodynamic profiling. J Infect Chemother 2003; 9: 292-296.
17. Olsen KM, Rudis MI, Rebuck JA, Hara J, Gelmont D, Mehdian R, Nelson C, Rupp ME: Effect of once-daily dosing vs. multiple daily dosing of tobramycin on enzyme markers of nephrotoxicity. Crit Care Med 2004; 32: 1678-1682.
18. Scaglione F: Can PK/PD be used in everyday clinical practice. Int J Antimicrob Agents 2002; 19: 349-353.
19. Schentag JJ, Gilliland KK, Paladino JA: What have we learned from pharmacokinetic and pharmacodynamic theories? Clin Infect Dis 2001; 32 (Suppl. 1): S39-46.
20. Jacobs MR: Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamc parameters. Clin Microbiol Infect. 2001; 7: 589-596.
21. Nightingale CH, Grant EM, Quintiliani R: Pharmacodynamics and pharmacokinetics of levofloxacin. Chemotherapy 2000; 46 (Suppl. 1): 6-14.
22. Wright DH, Brown GH, Peterson ML, Rotschafer JC: Application of fluoroquinolone pharmacodynamics. J Antimicrob Chemother 2000; 46: 669-683.
23. MacKenzie FM, Gould IM: The post-antibiotic effect. J Antimicrob Chemother 1993; 32: 519-537.
24. Odenholt I: Pharmacodynamic effects of subinhibitory antibiotic concentrations. Int J Antimicrob Agents 2001; 17: 1-8.
25. Mouton JW, Vinks AA: Is continuous infusion of beta-lactam antibiotics worthwhile? Efficacy and pharmacokinetics considerations. J Antimicrob Chemother 1996; 38: 5-15.
26. Craig W: Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 1995; 22: 89-96.
27. Hanes S, Wood G, Herling V, Croce M, Fabian T, Pritchard E, Boucher B: Intermittent and continuous ceftazidime infusion for critically ill trauma patients. Am J Surg 2000; 179: 436-440.
28. Mohr J, Wanger A, Rex J: Pharmacokinetic/pharmacodynamic modeling can help guide targeted antimicrobial therapy for nosocomial gram-negative infections in critically ill patients. Diagn Microbiol Infect Dis 2004; 48: 125-130.
29. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing, 12th informational supplement. Approved standard M100-S12. National Committee for Clinical Laboratory Standards, 2002; 22 (1).
30. MacGowan AP, Wise R: Establishing MIC breakpoints and the interpretation of in vitro susceptibility tests. J Antimicrob Chemother 2001; 48 (Suppl. S1): 17-28.
31. Estee L: Review of pharmacokinetics and pharmacodynamics of antimicrobial agents. Mayo Clin Proc 1998; 73: 1114-1122.
32. Warner S: Diagnostics+Therapy=Theranostics. Strategy requires teamwork, partnering, and tricky regulatory maneuvering. The Scientist 2004; 18: 38.
33. Amsden G, Duran M: Interpretation of antibacterial susceptibility reports: in vitro versus clinical break-points. Drugs 2001; 61: 163-166.
34. Ali MZ, Goetz MB: A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 1997; 24: 796-809.
35. Munckhof WJ, Grayson ML, Turnidge JD: A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses. J Antimicrob Chemother 1996; 37: 645-663.
36. Buijk SE, Mouton JW, Gyssens IC, Verbrugh HA, Bruining HA: Experience with a once-daily dosing program of aminoglycosides in critically ill patients. Intensive Care Med 2002; 28: 936-942.
37. Fantin B, Farinotti R, Thabaut A, Carbon C: Conditions for the emergence of resistance to cefpirome and ceftazidime in experimental endocarditis due to Pseudomonas aeruginosa. J Antimicrob Chemother 1994; 33: 563-569.
38. Pea F, Viale P: The antimicrobial therapy puzzle: Could pharmacokinetic-pharmacodynamic relationships be helpful in addressing the issue of appropriate pneumonia treatment incritically ill patiens? Clin Infect Dis 2006; 42: 1764-1771.
39. Turnidge JD: The pharmacodynamics of beta-lactams. Clin Infect Dis 1998; 27: 10-22.
40. Angus BJ, Smith MD, Suputtamongkol Y, Mattie H, Walsh AL, Wuthiekanun V, Chaowagul W, White NJ: Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis. Br J Clin Pharmacol 2000; 50: 184-191.
41. Craig W: The role of pharmacodynamics in effective treatment of community- acquired pathogens. Advanced Studies in Medicine 2002; 2: 126-134.
42. Lipman J, Wallis S, Rickard C: Low plasma cefepime levels in critically ill septic patients: pharmacokinetic modeling indicates improved troughs with revised dosing. Antimicrob Agents Chemother 1999; 43: 2559-2581.
43. Lipman J, Gomersall CD, Gin T, Joynt GM, Young RJ: Continuous infusion ceftazidime in intensive care: a randomized controlled trial. J Antimicrob Chemother 1999; 43: 309-311.
44. Kollef MH, Sherman G, Ward S, Fraser VJ: Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999; 115: 462-474.
45. MacGowan A, Bowker K: Continous infusion of beta-lactam antibiotics. Clin Pharmacokinet 1998; 35: 391-402.
46. van Zanten AR, Polderman KH: Rational use of antibiotics in the ICU: Optimum efficacy for the lowest cost; in: Yearbook of Intensive Care and Emergency Medicine (Ed.: Vincent JL), Springer-Verlag, Berlin, Heidelberg and New York, 2005: 337-348.
47. Nicolau DP, McNabb J, Lacy MK, Quintiliani R, Nightingale CH: Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia. Int J Antimicrob Agents 2001; 17: 497-504.
48. Jaruratanasirikul S, Sriwiriyajan S, Punyo J: Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection. Antimicrob Agents Chemother 2005; 49: 1337-1339.
49. Lorente L, Lorenzo L, Martin MM, Jimenez A, Mora ML: Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli. Ann Pharmacother 2006; 40: 219-223.
50. Zhou J, Dong Y, Zhao X, Lee S, Amin A, Ramaswamy S, Domagala J, Musser JM, Drlica K: Selection of antibiotic-resistant bacterial mutants: allelic diversity among fluoroquinolone-resistant mutations. J Infect Dis 2000; 182: 517-525.
51. Hyatt JM, Schentag JJ: Pharmacodynamic modeling of risk factors for ciprofloxacin resistance in Pseudomonas aeruginosa. Infect Control Hosp Epidemiol 2000; 21 (Suppl. 1): S9-11.
52. Lowdin E, Odenholt I, Cars O: In vitro studies of pharmacodynamic properties of vancomycin against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother 1998; 42: 2739-2744.
53. Knudsen JD, Fuursted K, Raber S, Espersen F, Frimodt-Moller N: Pharmacodynamics of glycopeptides in the mouse peritonitis model of Streptococcus pneumoniae or Staphylococcus aureus infection. Antimicrob Agents Chemother 2000; 44: 1247-1254.
54. Rello J, Sole-Violan J, Sa-Borges M, Garnacho-Montero J, Munoz E, Sirgo G, Olona M, Diaz E: Pneumonia caused by oxacillin-resistant Staphylococcus aureus treated with glycopeptides. Crit Care Med 2005; 33: 1983-1987.
55. Wysocki M, Delatour F, Faurisson F, Rauss A, Pean Y, Misset B, Thomas F, Timsit JF, Similowski T, Mentec H, Mier L, Dreyfuss D: Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother. 2001; 45: 2460-2467.
56. Bodi M, Ardanuy C, Olona M, Castander D, Diaz E, Rello J: Therapy of ventilator-associated pneumonia: the Tarragona strategy. Clin Microbiol Infect 2001; 7: 32-33.